Regulatory and other responses to the pharmaceutical opioid problem

Thomas Polasek, Melody Caramins, Graeme Suthers

Research output: Contribution to journalLetterpeer-review

1 Citation (Scopus)


To the Editor: We read with interest the article regarding Australia's approach to managing the challenges of pharmaceutical opioid utilisation.1 The various regulatory, service delivery and educational activities described would appear to provide a comprehensive response to this problem. However, we were surprised to note the absence of any reference to the potential of pharmacogenomics in identifying patients at increased risk of opioid toxicity.
Original languageEnglish
Pages (from-to)237-237.e1
Number of pages1
JournalMedical Journal of Australia
Issue number5
Publication statusPublished - Sept 2019
Externally publishedYes


  • Analgesics, opioid
  • Codeine
  • Pharmacogenomics


Dive into the research topics of 'Regulatory and other responses to the pharmaceutical opioid problem'. Together they form a unique fingerprint.

Cite this